Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Adlai Nortye Ltd. Sponsored ADR ( (ANL) ) has issued an announcement.
In the first half of 2025, Adlai Nortye reported progress across its oncology pipeline, with phase I trials ongoing for immunotherapy candidate AN8025 and oral PD-L1 inhibitor AN4005, which has moved into an expansion phase after showing encouraging safety and early efficacy in advanced tumors. The company also advanced its RAS-focused assets, planning to start a phase I study of oral pan-RAS(ON) inhibitor AN9025 in the first quarter of 2026, preparing an IND submission for CEACAM5-targeting ADC AN4035 for mid-2026, and continuing the ARTEMIS phase II rectal cancer study of EP4 antagonist AN0025, following encouraging phase Ib response rates and with futility analysis expected by the first quarter of 2026. Financially, for the six months ended June 30, 2025, Adlai Nortye’s cash and cash equivalents fell to US$44.1 million from US$60.9 million at year-end 2024 while adding US$18.2 million in restricted cash, but its net loss narrowed by 33.6% year-on-year to US$18.3 million as operating cash burn halved, driven mainly by a 41.4% reduction in R&D expenses and lower share-based compensation, indicating tighter cost control as it advances multiple early- and mid-stage clinical programs.
More about Adlai Nortye Ltd. Sponsored ADR
Adlai Nortye Ltd. (Nasdaq: ANL) is a global clinical-stage oncology drug developer with dual R&D hubs in the U.S. and China, focused on next-generation cancer immunotherapies and RAS-targeted treatments. Its pipeline includes AN8025, a tri-specific fusion protein modulating T cells and antigen-presenting cells; AN4005, an oral small-molecule PD-L1 inhibitor; AN9025, an oral pan-RAS(ON) inhibitor aimed at a broad range of RAS-mutant tumors; and AN4035, a CEACAM5-targeting antibody-drug conjugate delivering a pan-RAS(ON) payload, positioning the company in highly competitive segments of solid tumor therapy.
Average Trading Volume: 18,021
Technical Sentiment Signal: Hold
Current Market Cap: $60.52M
For detailed information about ANL stock, go to TipRanks’ Stock Analysis page.